CTSS and neoplasm: Such example is FDA approved therapeutic Adcetris® (brentuximab vedotin), an antibody-drug conjugate containing cathepsin-sensitive peptide linker, enabling selective release of cytotoxic payload into the tumor tissue (111, 112).